Boston Scientific Corp.

Strong Financial Performance: Boston Scientific reported Q1 2025 organic sales growth of 18%, exceeding expectations of 14% to 16%. Total operational sales increased by 22%, with adjusted EPS growing by 34% to $0.75, demonstrating solid financial traction and exceeding guidance.

Revised Full-Year Guidance: The company raised its full-year 2025 organic revenue growth forecast from 10-12% to 12-14%, driven by strength in their cardiology portfolio. Q2 guidance indicates organic growth of 13-15%, which signals continued positive momentum in sales.

Tariffs and Expense Management: Boston Scientific anticipates a $200 million headwind from tariffs in 2025, primarily affecting the second half of the year. The company plans to offset this by increasing sales and implementing targeted discretionary spending reductions. This highlights potential challenges but also shows their ability to manage costs effectively.